quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:44:55·833d
NEWSRelease
180 Life Sciences Corp. logo
Atreca Inc. logo
Clearmind Medicine Inc. logo
+3

US Stocks Higher; Inflation Rate Increases To 3.4% In December

ATNF· 180 Life Sciences Corp.BCEL· Atreca Inc.CMND· Clearmind Medicine Inc.MLEC· Moolec Science SASPEC· Spectaire Holdings Inc.YGF· YanGuFang International Group Co. Ltd.
Health CareFinanceIndustrials
Original source

Companies

  • ATNF
    180 Life Sciences Corp.
    Health Care
  • BCEL
    Atreca Inc.
    Health Care
  • CMND
    Clearmind Medicine Inc.
    Health Care
  • MLEC
    Moolec Science SA
    Finance
  • SPEC
    Spectaire Holdings Inc.
    Industrials
  • YGF
    YanGuFang International Group Co. Ltd.
    Consumer Staples

Recent analyst ratings

  • Sep 27MLECUpdateROTH MKM$5.00
  • Mar 4BCELUpdateStifel$14.00
  • Sep 15ATNFUpdateMaxim Group$11.00

Related

  • SEC2d
    SEC Form 6-K filed by Clearmind Medicine Inc.
  • SEC3d
    SEC Form 6-K filed by Clearmind Medicine Inc.
  • SEC3d
    SEC Form 6-K filed by Clearmind Medicine Inc.
  • PR3d
    Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
  • PR3d
    Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
  • SEC8d
    SEC Form 6-K filed by Moolec Science SA
  • INSIDER8d
    SEC Form 3 filed by new insider Core Daniel Joaquin
  • SEC8d
    SEC Form 6-K filed by Clearmind Medicine Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022